Ashland Inc. · NYSE:ASH
Ashland — Ashland Global Holdings — Investor Presentation (June 2022)
24 slides from Ashland's investor presentation, Jun 9, 2022
Slide 1: Corporate Presentation
responsibly solving for a better world June 9, 2022 investor.ashland.com corporate presentation Exhibit 99.1
Slide 2: Forward looking statements
forward looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words
Slide 3: Agenda
agenda corporate overview financial performance closing comments Q&A
Slide 4: Corporate overview
corporate overview
Slide 5: Ashland at a glance
Ashland1 sales $2.3 billion adjusted EBITDA $547 million adj. EBITDA margin 24.3 % size and critical mass to succeed strong financials diversification of three segments geographically well positioned 1 All figures as of the last twelve months ended March 31, 2022. All figures are presented on an adj
Slide 6: Additives and specialty ingredients company focused on consumer-driven end markets
>$2 Bn additives and specialty ingredients company focused on consumer-driven end markets high sustainability non- nature-derived consumer market-focused industrial additives and ingredients intermediates unique specialty profile high sustainability (natural, nature-derived, inherently biodegradable
Slide 7: Far reaching global footprint
employees by region — NA 53% EMEA 21% AP 16% LATAM 10% 3,800 employees far reaching global footprint
Slide 8: Priorities
priorities rebalanced our innovation portfolio consumer-market focus intensifying ESG initiatives geographic expansion bolt-on M&A Pharma Personal Care Coatings profitable growth prioritize organic growth CAPEX improved working capital efficiency strategically aligned M&A efficient balance sheet con
Slide 9: Megatrends and growth
megatrends and growth grow leadership position in oral solid dosage (OSD) expand injectables & biomed consumables leverage portfolio in nutrition drive geographic growth of our rheology franchise expand global architectural coatings franchise beyond rheology drive margin enhancement in other busines
Slide 10: Innovation is core to driving value
innovation is core to driving value record number of new product introductions 100% of FY22 launches focused on growth 89% of the launches FY22 year-to-date are highly sustainable disciplined innovation process (project and portfolio management) business unit ownership of strategy and innovation pri
Slide 11: ESG is embedded in our strategy
ESG is embedded in our strategy our purpose- to responsibly solve for a better world governance management and board ESG literacy social global STEM and education focus; inclusion and diversity environment core driver of innovations portfolio i&d Science Based Targets (SBTi)
Slide 12: Long term growth objectives
long term growth objectives compelling opportunity for growth, margin expansion and cash generation +5 – 6% market growth 2-3% objective: +200-400bps above market organic sales growth +100 bps per year EBITDA margin expansion 1 bolt-on per year objective: sales $50-$100MM EBITDA >30% bolt-on acquisi
Slide 13: Value potential: undervalued compared to peer group
value potential undervalued compared to peer group Ashland (1) Specialty Additives 29% I&S 6% Life Sciences 35% Personal Care & Household 30% company a Performance Technologies 30% Industrial Chemicals 7% Personal Care 34% Life Sciences 29% company b Scent 39% Taste 61% company c Taste & Wellbeing 5
Slide 14: Creating value for all stakeholders
creating value for all stake holders sales of > $3.2 billion EBITDA of ~$900 million EBITDA margins >30% cumulative free cash flow of $2.1 – $2.6 billion by fiscal year 2026….. over the next 5 years, we expect to invest ~$2.0 – $2.5 billion in bolt-on acquisitions and return ~$1.5 billion to shareho
Slide 15: Financial performance
financial performance
Slide 16: Strong, resilient performance
strong, resilient performance resilient sales, profit and margins exceeding pre-pandemic levels strong cost recovery in a high inflation environment innovation record number of new product introductions growing significantly in a world of accelerating change profitable agile flexible adaptive growth
Slide 17: Outstanding Q2 performance
outstanding Q2 performance1 sales adjusted EBITDA adjusted EBITDA % adjusted EPS2 broad-based sales growth +41 % $163 MM strong price realization and mix improvement +420 bps 27.0 % leadership position in high-value end markets +79 % $1.50 strong returns to shareholders Comparisons versus prior year
Slide 18: Outlook
outlook full-year guidance maintained agile, disciplined, focused on what we can control risks reliability / cost of ocean freight rising global energy costs general cost inflation; foreign currency lag impact of pricing recover in Q4 impact of Russia /Ukraine war and China lockdowns forward looking
Slide 19: Ashland - always solving
ef Ashland ‘always solving
Slide 20: Focused additives and specialty ingredients company
focused additives and specialty ingredients company Ashland leadership positions in high-quality markets and with exciting profitable growth opportunities strong technology, commercial and operations capabilities global infrastructure compelling growth platforms with scale and sustainable competitiv
Slide 21: Q&A
Q&A
Slide 22: Ashland - always solving
“<t Ashland always solving
Slide 23: Appendix
appendix
Slide 24: Reconciliation of Non-GAAP Data for 12 Months Ended March 31, 2022
Ashland Global Holdings Inc. and Consolidated Subsidiaries Reconciliation of Non-GAAP Data for 12 Months Ended March 31, 2022 ($ millions, except percentages) Sales1 Q2 22 Q1 22 Q4 21 Q3 21 Total Q2 21 Life Sciences $204 $170 $189 $193 $756 $185 Personal Care 172 147 183 147 649 137 Specialty Additi
Ashland Global Holdings — Investor Presentation (June 2022) on 6ix